# A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer

Source: https://onco.cc/trials/nct06990880/  
OnCo record `nct06990880` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of GSK5458514 in prostate cancer, run by GlaxoSmithKline, now recruiting.

## Summary

A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer is a phase 1/2 interventional study registered as NCT06990880 by GlaxoSmithKline, with 85 participants planned, started 2025-06-12 and due to reach its primary completion in 2027-10-26. Interventions recorded: GSK5458514.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06990880
- Phase: 1/2
- Setting: A Phase 1/2 First-Time-In-Human, Open-Label, Multicenter, Dose Escalation and Expansion Study of GSK5458514 PSMA Targeting T Cell Engager Alone or in Combination With Other Anti-Cancer Agents in Adult Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Sponsor: GlaxoSmithKline
- Enrolled: 85

## Sources

- ClinicalTrials.gov NCT06990880: https://clinicaltrials.gov/study/NCT06990880

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- companies: [GSK](https://onco.cc/companies/gsk/)

---
JSON: https://onco.cc/api/v1/entities/nct06990880.json